<!DOCTYPE html>
<html lang="en">
<head><!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-N4XZHNC');</script> <!-- End Google Tag Manager -->

<title>Androgen Deprivation Therapy: Drugs and Adverse Effects</title>
  <meta charset="utf-8">
  
  <link href="urology2.css" rel="stylesheet">

<meta name="keywords" content="gnrh antagonists, degarelix, abarelix" >
<meta name="description" content="Androgen deprivation therapy (ADT) is a treatment option for advanced prostate cancer, the relevant side effects and drugs are presented in detail...., from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
 </head>

<body><!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N4XZHNC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="https://www.urology-textbook.com/index.html">
	   <p><span style="font-size: 1.2em;">Urology Textbook</span><br>
       
       <span style="font-size: 0.8em;">Clinical Essentials</span>
       <br>
       <span style="font-size: 0.6em;">By Dirk Manski, MD</span></p>
    </a>  
</header>
<main> 
<article>
<nav role="navigation">
<div id="menuToggle">
<input type="checkbox" id="menuCheckbox" />
     <span></span>
    <span></span>
    <span></span>
<ul id="menu">
<li>
        <a href="https://www.urology-textbook.com/anatomy.html">
          <label for="menuCheckbox" onclick="this.parentNode.click();">Anatomy</label>
        </a>
      </li>
<li><a href="https://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="https://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="https://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="https://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="https://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="https://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="https://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="https://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="https://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="https://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="https://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="https://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="https://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="https://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="https://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="https://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="https://www.urology-textbook.com/links.html">Links</a></li>
</ul>

</div>
</nav>

<p id="brotkrumen">&nbsp;You are here: <a href="https://www.urology-textbook.com/index.html">Urology Textbook</a> &gt; <a href="https://www.urology-textbook.com/pharmacology.html">Drugs in Urology</a> &gt; Androgen Deprivation Therapy</p>

<h1>Androgen Deprivation Therapy: Drugs and Adverse Effects</h1>

<p>Androgen deprivation therapy (ADT) is a treatment option for advanced prostate cancer in the following situations:</p>

    <ul>
        <li><a href="https://www.urology-textbook.com/prostate-cancer-hormonal-therapy.html">Metastatic prostate cancer</a></li>
        <li>Biochemical progression of prostate cancer with no detectable metastases and a PSA doubling time below three months</li>
        <li>Adjuvant therapy of advanced prostate cancer after <a href="https://www.urology-textbook.com/retropubic-radical-prostatectomy.html">radical prostatectomy</a> or <a href="https://www.urology-textbook.com/prostate-cancer-radiation-therapy.html">radiation therapy</a></li>
        <li>Conservative treatment of locally advanced prostate cancer with LUTS</li>
        <li>Lowering prostate volume before <a href="https://www.urology-textbook.com/prostate-cancer-brachytherapy.html">brachytherapy</a></li>
    </ul>
    
<h3>Classification of Drugs for Androgen Deprivation Therapy</h3>

    <ul>
        <li>Classic androgen receptor antagonists: nonsteroidal drugs are <a href="https://www.urology-textbook.com/bicalutamide.html">bicalutamide</a> and <a href="https://www.urology-textbook.com/flutamide.html">flutamide</a>. Cyproterone acetate is a classic steroidal antiandrogen with a progestational effect, which causes additional central inhibition of the testosterone concentration. </li>
        <li><a href="https://www.urology-textbook.com/gnrh-agonists.html">GnRH agonists: Buserelin, Goserelin, Histrelin, Leuprorelin, and Triptorelin</a></li>
        <li><a href="https://www.urology-textbook.com/gnrh-antagonists.html">GnRH antagonists: degarelix and relugolix</a></li>
        <li>Estrogens: Fosfestrol</li>
        <li>Androgen synthesis inhibitors: <a href="https://www.urology-textbook.com/abiraterone.html">Abiraterone</a>.</li>
        <li>Modern androgen receptor antagonists: <a href="https://www.urology-textbook.com/enzalutamide.html">Enzalutamide</a>, <a href="https://www.urology-textbook.com/apalutamide.html">Apalutamide</a>, <a href="https://www.urology-textbook.com/darolutamide.html">Darolutamide</a>.</li>
    </ul>
    
<h2>Principles of Androgen Deprivation Therapy</h2>

<p>The individual therapy options are applied sequentially or in combination depending on disease progression and response [fig. <a href="#PCA_M1_english">androgen deprivation therapy of prostate cancer</a>]. Please see also the section on <a href="https://www.urology-textbook.com/prostate-cancer-hormonal-therapy.html">metastatic prostate cancer</a> for details.</p>

<a NAME="PCA_M1_english"> </a>
<table width=100%>
    <caption> <strong>Androgen deprivation therapy (ADT) of advanced prostate cancer:</strong> <strong>1:</strong> A maximum of 2--4 visible bone metastases (depending on the study) in conventional imaging. <strong>2:</strong> Options are orchiectomy, GnRH analogs, or GnRH antagonists. <strong>3:</strong> At least two of the following risk factors: Gleason score &ge;8, at least 3 bone metastases, or evidence of visceral metastases. <strong>4:</strong> At least 4 bone metastases (including at least one beyond the pelvis or spine) or the presence of visceral metastases. <strong>6:</strong> M0 CRPC with a PSA doubling time of less than ten months. <strong>7:</strong> The order of the sequence is not defined. </caption>
<tr><td><img src="https://images2.urology-textbook.com/PCA_M1_engl.jpg" title="Hormonal therapy of advanced prostate cancer" alt="Flowchart Hormonal therapy of advanced prostate cancer"> </td> </tr>
</table>    

<h3>General Adverse Effects of Androgen Deprivation Therapy</h3>

<p>Androgen Deprivation Therapy (ADT) leads to significant side effects, especially in long-term use. Androgen receptor antagonists do not lower the testosterone concentration and cause fewer side effects (except <a href="https://www.urology-textbook.com/gynecomastia.html">gynecomastia</a>) compared to orchiectomy or GnRH modulators. General measures for the prevention of the side effects listed below are increasing physical activity, striving for a normal body weight, eating a vitamin-rich, healthy diet, and not smoking (Nguyen et al., 2015).</p>

<h4>Hot flashes: </h4>
<p>Hot flashes are very common; treatment options are (off-label use) Clonidine, Cyproteronacetat, Venlafaxine, or Paroxetine (Loprinzi et al., 2004).</p>

<h4>Erectile dysfunction and loss of libido:</h4>
<p>ADT leads to <a href="https://www.urology-textbook.com/erectile-dysfunction.html">severe erectile dysfunction</a> (over 80%) and loss of libido (over 95%). Effective treatment of libido loss is not possible, but the psychological burden of sexual dysfunction is low. Therapeutic options against erectile dysfunction (<a href="https://www.urology-textbook.com/erectile-dysfunction-treatment.html">PDE5 inhibitors or SKAT</a>) are not often requested. Long-term ADT leads to reductions in both penile and testicular size.</p>
 
<h4>Gynecomastia and mastodynia:</h4>
<p>Gynecomastia is a very common side effect of androgen receptor antagonists. When bicalutamide 150 mg is administered alone, the risk for gynecomastia is well over 70% after one year. The prophylactic single irradiation with 12&ndash;18&nbsp;Gy of the mammary glands before treatment significantly lowers the risk to 30&ndash;50 %. The risk of gynecomastia for combined androgen deprivation therapy is lower and amounts to about 20%. Gynecomastia is rare if GnRH modulators are used alone. </p>

<p>The prophylactic administration of tamoxifen (off-label) is more potent than the irradiation to reduce the frequency of gynecomastia (10% vs. 30&ndash;50%). The dosage of tamoxifen is 20&nbsp;mg/d. The effect of tamoxifen does not appear to affect androgen deprivation therapy and the biological behavior of prostate cancer (Fradet et al., 2007). Another therapy option is subcutaneous mastectomy.</p>

<h4>Cognitive function and mood disorders:</h4>
<p>Cognitive function is disturbed by ADT. Furthermore, decreased libido, fatigue, and episodes of depression (relative risk RR of 8) are more common.</p>

<h4>Metabolic changes:</h4>
<p>Androgen deprivation leads to a loss of muscle mass and increase in body fat, after a year the body weight has increased on average 2&ndash;4%. The risk of metabolic syndrome and type II diabetes is also significantly increased.</p>

<h4>Cardiovascular risks:</h4>
<p>Androgen deprivation leads to an increase in cardiovascular diseases (the relative risk in brackets): CHD (RR 1.2), myocardial infarction (RR 1.1), life-threatening cardiac arrhythmias, or sudden cardiac death (RR 1.16). Cardiovascular mortality increases by 1&ndash;6% compared to the placebo group, depending on the study and follow-up period (Levine et al., 2010).</p>

<h4>Osteoporosis and fractures:</h4>
<p>Osteoporosis is a common complication of long-term ADT with GnRH modulators or castration (Diamond et al., 2004b). The administration of androgen receptor blockers (e.g., Bicalutamide) is not associated with osteoporosis (SmithMR et al, 2004). The fracture rate among men surviving at least 5 years is 19% with ADT versus 13% without ADT. All patients with a long-term prognosis should receive prophylactic vitamin D (800&ndash;1000&nbsp;IU) and calcium (1000&nbsp;mg). Additional treatment options for osteoporosis with increased fracture risk include bisphosphonates or denosumab.</p>

<h4>Anemia:</h4>
<p>Normochromic normocytic anemia develops in patients with long-term ADT, which responds well to erythropoietin (Choo et al., 2005).</p>
<br>
<br>

<div id="ad-footer">
<!-- ad-footer -->
<ins class="adsbygoogle"
     style="display:inline-block;width:500px;height:250px"
     data-ad-client="ca-pub-9284927104423861"
     data-ad-slot="8746163219"></ins>
 <script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>
</div>
<br><table id="navigation_unten">
<tr>
 
<td><a href="https://www.urology-textbook.com/gnrh-agonists.html">GnRH agonists</a></td>
<td><a class="nav4" href="https://www.urology-textbook.com/index-urology.html">Index</a></td>
<td><a class="nav3" href="https://www.urology-textbook.com/flutamide.html">Flutamide</a></td>
 
</tr>
</table>

<br>
<br>
Index: <a href="https://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="https://www.urology-textbook.com/index-urology-a.html">A</a> <a href="https://www.urology-textbook.com/index-urology-b.html">B</a> <a href="https://www.urology-textbook.com/index-urology-c.html">C</a> <a href="https://www.urology-textbook.com/index-urology-d.html">D</a> <a href="https://www.urology-textbook.com/index-urology-e.html">E</a> <a href="https://www.urology-textbook.com/index-urology-f.html">F</a> <a href="https://www.urology-textbook.com/index-urology-g.html">G</a> <a href="https://www.urology-textbook.com/index-urology-h.html">H</a> <a href="https://www.urology-textbook.com/index-urology-i.html">I</a> <a href="https://www.urology-textbook.com/index-urology-j.html">J</a> <a href="https://www.urology-textbook.com/index-urology-k.html">K</a> <a href="https://www.urology-textbook.com/index-urology-l.html">L</a> <a href="https://www.urology-textbook.com/index-urology-m.html">M</a> <a href="https://www.urology-textbook.com/index-urology-n.html">N</a> <a href="https://www.urology-textbook.com/index-urology-o.html">O</a> <a href="https://www.urology-textbook.com/index-urology-p.html">P</a> <a href="https://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="https://www.urology-textbook.com/index-urology-r.html">R</a> <a href="https://www.urology-textbook.com/index-urology-s.html">S</a> <a href="https://www.urology-textbook.com/index-urology-t.html">T</a> <a href="https://www.urology-textbook.com/index-urology-u.html">U</a> <a href="https://www.urology-textbook.com/index-urology-v.html">V</a> <a href="https://www.urology-textbook.com/index-urology-w.html">W</a> <a href="https://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<br>
<h3>References</h3>


<p><a NAME="Anderson2003">
    Anderson 2003 A<SMALL>NDERSON</SMALL>, J.:
    </a>
     The role of antiandrogen monotherapy in the treatment of prostate
      cancer.
    <br> In: <I>BJU Int</I>
    <br> 91 (2003), Nr.&nbsp;5, S.&nbsp;455&ndash;61.</p>


<p>
<a NAME="Choo2005">
Choo u.a. 2005 C<SMALL>HOO</SMALL>, R.&nbsp;; C<SMALL>HANDER</SMALL>, S.&nbsp;;
  D<SMALL>ANJOUX</SMALL>, C.&nbsp;; M<SMALL>ORTON</SMALL>, G.&nbsp;; P<SMALL>EARCE</SMALL>, A.&nbsp;;
  D<SMALL>EBOER</SMALL>, G.&nbsp;; S<SMALL>ZUMACHER</SMALL>, E.&nbsp;; L<SMALL>OBLAW</SMALL>, A.&nbsp;;
  C<SMALL>HEUNG</SMALL>, P.&nbsp;; W<SMALL>OO</SMALL>, T.:
</a>
 How are hemoglobin levels affected by androgen deprivation in
  non-metastatic prostate cancer patients?
<br> In: <I>Can J Urol</I>
    <br> 12 (2005), Nr.&nbsp;1, S.&nbsp;2547&ndash;52.</p>

<p>
<a NAME="Diamond2004b">
Diamond u.a. 2004 D<SMALL>IAMOND</SMALL>, T.&nbsp;H.&nbsp;; H<SMALL>IGANO</SMALL>,
  C.&nbsp;S.&nbsp;; S<SMALL>MITH</SMALL>, M.&nbsp;R.&nbsp;; G<SMALL>UISE</SMALL>, T.&nbsp;A.&nbsp;; S<SMALL>INGER</SMALL>,
  F.&nbsp;R.:
</a>
 Osteoporosis in men with prostate carcinoma receiving
  androgen-deprivation therapy: recommendations for diagnosis and therapies.
<br> In: <I>Cancer</I>
    <br> 100 (2004), Nr.&nbsp;5, S.&nbsp;892&ndash;9.</p>

<p>
<a NAME="Fradet2007">
Fradet u.a. 2007 F<SMALL>RADET</SMALL>, Yves&nbsp;; E<SMALL>GERDIE</SMALL>,
  Blair&nbsp;; A<SMALL>NDERSEN</SMALL>, Morten&nbsp;; T<SMALL>AMMELA</SMALL>, Teuvo L&nbsp;J.&nbsp;;
  N<SMALL>ACHABE</SMALL>, Mahmoud&nbsp;; A<SMALL>RMSTRONG</SMALL>, Jon&nbsp;; M<SMALL>ORRIS</SMALL>,
  Thomas&nbsp;; N<SMALL>AVANI</SMALL>, Sunil:
</a>
 Tamoxifen as prophylaxis for prevention of gynaecomastia and breast
  pain associated with bicalutamide 150&nbsp;mg monotherapy in patients with
  prostate cancer: a randomised, placebo-controlled, dose-response study.
<br> In: <I>Eur Urol</I>
    <br> 52 (2007), Jul, Nr.&nbsp;1, S.&nbsp;106&ndash;114.</p>


<p><a name="Levine2010">Levine, Glenn N; D'Amico, Anthony V; Berger, Peter; 
        Clark, Peter E; Eckel, Robert H; Keating, Nancy L; Milani, Richard V; 
        Sagalowsky, Arthur I; Smith, Matthew R; Zakai, Neil; on Clinical 
        Cardiology, American Heart Association Council; on Epidemiology, Council; 
        Prevention, the American Cancer Society &amp; the American Urological 
        Association</a>
    Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: 
        endorsed by the American Society for Radiation Oncology.<br>
        <em>CA Cancer J Clin, </em><b>2010</b><i>, 60</i>, 194-201</p>

<p>
<a NAME="Loblaw2004">
Loblaw u.a. 2004 L<SMALL>OBLAW</SMALL>, D.&nbsp;A.&nbsp;; M<SMALL>ENDELSON</SMALL>,
  D.&nbsp;S.&nbsp;; T<SMALL>ALCOTT</SMALL>, J.&nbsp;A.&nbsp;; V<SMALL>IRGO</SMALL>, K.&nbsp;S.&nbsp;;
  S<SMALL>OMERFIELD</SMALL>, M.&nbsp;R.&nbsp;; B<SMALL>EN-</SMALL>J<SMALL>OSEF</SMALL>, E.&nbsp;; M<SMALL>IDDLETON</SMALL>,
  R.&nbsp;; P<SMALL>ORTERFIELD</SMALL>, H.&nbsp;; S<SMALL>HARP</SMALL>, S.&nbsp;A.&nbsp;; S<SMALL>MITH</SMALL>,
  T.&nbsp;J.&nbsp;; T<SMALL>APLIN</SMALL>, M.&nbsp;E.&nbsp;; V<SMALL>OGELZANG</SMALL>, N.&nbsp;J.&nbsp;; W<SMALL>ADE</SMALL>,
  Jr.&nbsp;; B<SMALL>ENNETT</SMALL>, C.&nbsp;L.&nbsp;; S<SMALL>CHER</SMALL>, H.&nbsp;I.:
</a>
 American Society of Clinical Oncology recommendations for the initial
  hormonal management of androgen-sensitive metastatic, recurrent, or
  progressive prostate cancer.
<br> In: <I>J Clin Oncol</I>
    <br> 22 (2004), Nr.&nbsp;14, S.&nbsp;2927&ndash;41.</p>

<p>
<a NAME="Loprinzi2004">
Loprinzi u.a. 2004 L<SMALL>OPRINZI</SMALL>, C.&nbsp;L.&nbsp;; B<SMALL>ARTON</SMALL>,
  D.&nbsp;L.&nbsp;; C<SMALL>ARPENTER</SMALL>, L.&nbsp;A.&nbsp;; S<SMALL>LOAN</SMALL>, J.&nbsp;A.&nbsp;; N<SMALL>OVOTNY</SMALL>,
  P.&nbsp;J.&nbsp;; G<SMALL>ETTMAN</SMALL>, M.&nbsp;T.&nbsp;; C<SMALL>HRISTENSEN</SMALL>, B.&nbsp;J.:
</a>
 Pilot evaluation of paroxetine for treating hot flashes in men.
<br> In: <I>Mayo Clin Proc</I>
    <br> 79 (2004), Nr.&nbsp;10, S.&nbsp;1247&ndash;51.</p>

<p>
<a NAME="Montgomery2005">
Montgomery u.a. 2005 M<SMALL>ONTGOMERY</SMALL>, B.&nbsp;S.&nbsp;;
  B<SMALL>ORWELL</SMALL>, J.&nbsp;P.&nbsp;; H<SMALL>IGGINS</SMALL>, D.&nbsp;M.:
</a>
 Does needle size matter? Patient experience of luteinising
  hormone-releasing hormone analogue injection.
<br> In: <I>Prostate Cancer Prostatic Dis</I>
    <br> 8 (2005), Nr.&nbsp;1, S.&nbsp;66&ndash;8.</p>

<p>
<a NAME="Miyamoto2004">
Miyamoto u.a. 2004 M<SMALL>IYAMOTO</SMALL>, H.&nbsp;; M<SMALL>ESSING</SMALL>,
  E.&nbsp;M.&nbsp;; C<SMALL>HANG</SMALL>, C.:
</a>
 Androgen deprivation therapy for prostate cancer: current status and
  future prospects.
<br> In: <I>Prostate</I>
    <br> 61 (2004), Nr.&nbsp;4, S.&nbsp;332&ndash;53.</p>

<p>
<a NAME="Perdona2005">
Perdona u.a. 2005 P<SMALL>ERDONA</SMALL>, S.&nbsp;; A<SMALL>UTORINO</SMALL>, R.&nbsp;;
  D<SMALL>E&nbsp;</SMALL>P<SMALL>LACIDO</SMALL>, S.&nbsp;; D&rsquo;A<SMALL>RMIENTO</SMALL>, M.&nbsp;; G<SMALL>ALLO</SMALL>, A.&nbsp;;
  D<SMALL>AMIANO</SMALL>, R.&nbsp;; P<SMALL>INGITORE</SMALL>, D.&nbsp;; G<SMALL>ALLO</SMALL>, L.&nbsp;;
  D<SMALL>E&nbsp;</SMALL>S<SMALL>IO</SMALL>, M.&nbsp;; B<SMALL>IANCO</SMALL>, A.&nbsp;R.&nbsp;; D<SMALL>I&nbsp;</SMALL>L<SMALL>ORENZO</SMALL>, G.:
</a>
 Efficacy of tamoxifen and radiotherapy for prevention and treatment
  of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a
  randomised controlled trial.
<br> In: <I>Lancet Oncol</I>
    <br> 6 (2005), Nr.&nbsp;5, S.&nbsp;295&ndash;300.</p>

<p>
<a NAME="Sieber2004">
Sieber u.a. 2004 S<SMALL>IEBER</SMALL>, P.&nbsp;R.&nbsp;; K<SMALL>EILLER</SMALL>,
  D.&nbsp;L.&nbsp;; K<SMALL>AHNOSKI</SMALL>, R.&nbsp;J.&nbsp;; G<SMALL>ALLO</SMALL>, J.&nbsp;; M<SMALL>C</SMALL>F<SMALL>ADDEN</SMALL>,
  S.:
</a>
 Bicalutamide 150&nbsp;mg maintains bone mineral density during monotherapy
  for localized or locally advanced prostate cancer.
<br> In: <I>J Urol</I>
    <br> 171 (2004), Nr.&nbsp;6 Pt 1, S.&nbsp;2272&ndash;6, quiz 2435</p>

<p>
<a NAME="Smith2003a">
Smith u.a. 2003 S<SMALL>MITH</SMALL>, M.&nbsp;R.&nbsp;; E<SMALL>ASTHAM</SMALL>, J.&nbsp;;
  G<SMALL>LEASON</SMALL>, D.&nbsp;M.&nbsp;; S<SMALL>HASHA</SMALL>, D.&nbsp;; T<SMALL>CHEKMEDYIAN</SMALL>, S.&nbsp;;
  Z<SMALL>INNER</SMALL>, N.:
</a>
 Randomized controlled trial of <a href="https://www.urologielehrbuch.de/zoledronat.html">zoledronat</a> to prevent bone loss
  in men receiving androgen deprivation therapy for nonmetastatic prostate
  cancer.
<br> In: <I>J Urol</I>
    <br> 169 (2003), Nr.&nbsp;6, S.&nbsp;2008&ndash;12.</p>

<p>
<a NAME="Smith2004a">
Smith u.a. 2004a S<SMALL>MITH</SMALL>, M.&nbsp;R.&nbsp;;
  F<SMALL>ALLON</SMALL>, M.&nbsp;A.&nbsp;; L<SMALL>EE</SMALL>, H.&nbsp;; F<SMALL>INKELSTEIN</SMALL>, J.&nbsp;S.:
</a>
 Raloxifene to prevent gonadotropin-releasing hormone agonist-induced
  bone loss in men with prostate cancer: a randomized controlled trial.
<br> In: <I>J Clin Endocrinol Metab</I>
    <br> 89 (2004), Nr.&nbsp;8, S.&nbsp;3841&ndash;6.</p>

<p>
<a NAME="SmithMR2004">
Smith u.a. 2004b S<SMALL>MITH</SMALL>, M.&nbsp;R.&nbsp;;
  G<SMALL>OODE</SMALL>, M.&nbsp;; Z<SMALL>IETMAN</SMALL>, A.&nbsp;L.&nbsp;; M<SMALL>C</SMALL>G<SMALL>OVERN</SMALL>, F.&nbsp;J.&nbsp;;
  L<SMALL>EE</SMALL>, H.&nbsp;; F<SMALL>INKELSTEIN</SMALL>, J.&nbsp;S.:
</a>
 Bicalutamide monotherapy versus leuprolide monotherapy for prostate
  cancer: effects on bone mineral density and body composition.
<br> In: <I>J Clin Oncol</I>
    <br> 22 (2004), Nr.&nbsp;13, S.&nbsp;2546&ndash;53.</p>

<p>
<a NAME="Tyrrell2004">
Tyrrell u.a. 2004 T<SMALL>YRRELL</SMALL>, C.&nbsp;J.&nbsp;; P<SMALL>AYNE</SMALL>, H.&nbsp;;
  T<SMALL>AMMELA</SMALL>, T.&nbsp;L.&nbsp;; B<SMALL>AKKE</SMALL>, A.&nbsp;; L<SMALL>ODDING</SMALL>, P.&nbsp;;
  G<SMALL>OEDHALS</SMALL>, L.&nbsp;; V<SMALL>AN&nbsp;</SMALL>E<SMALL>RPS</SMALL>, P.&nbsp;; B<SMALL>OON</SMALL>, T.&nbsp;;
  V<SMALL>AN </SMALL>D<SMALL>E&nbsp;</SMALL>B<SMALL>EEK</SMALL>, C.&nbsp;; A<SMALL>NDERSSON</SMALL>, S.&nbsp;O.&nbsp;; M<SMALL>ORRIS</SMALL>, T.&nbsp;;
  C<SMALL>ARROLL</SMALL>, K.:
</a>
 Prophylactic breast irradiation with a single dose of electron beam
  radiotherapy (10 Gy) significantly reduces the incidence of
  bicalutamide-induced gynecomastia.
<br> In: <I>Int J Radiat Oncol Biol Phys</I>
    <br> 60 (2004), Nr.&nbsp;2, S.&nbsp;476&ndash;83.</p>

<p>
<a NAME="Widmark2003">
Widmark u.a. 2003 W<SMALL>IDMARK</SMALL>, A.&nbsp;; F<SMALL>OSSA</SMALL>, S.&nbsp;D.&nbsp;;
  L<SMALL>UNDMO</SMALL>, P.&nbsp;; D<SMALL>AMBER</SMALL>, J.&nbsp;E.&nbsp;; V<SMALL>AAGE</SMALL>, S.&nbsp;;
  D<SMALL>AMBER</SMALL>, L.&nbsp;; W<SMALL>IKLUND</SMALL>, F.&nbsp;; K<SMALL>LEPP</SMALL>, O.:
</a>
 Does prophylactic breast irradiation prevent antiandrogen-induced
  gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial
  SPCG-7/SFUO-3.
<br> In: <I>Urology</I>
    <br> 61 (2003), Nr.&nbsp;1, S.&nbsp;145&ndash;51.</p>



<br>
<br>
<p><img src="https://images0.urology-textbook.com/deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/antiandrogene-therapie.html">Antiandrogene Therapie</a></p>
<br> <br><h3>Urology-Textbook.com – Choose the Ad-Free, Professional Resource</h3>
<p>This website is designed for physicians and medical professionals. It presents diseases of the genital organs through detailed text and images. Some content may not be suitable for children or sensitive readers. Many illustrations are available exclusively to Steady members. Are you a physician and interested in supporting this project? <a href="https://steady.page/de/urology/about">Join Steady to unlock full access</a> to all images and enjoy an ad-free experience. Try it free for 7 days&mdash;no obligation. </p>

<p><strong>New release:</strong> The first edition of the Urology Textbook as an e-book&mdash;ideal for offline reading and quick reference. With over 1300 pages and hundreds of illustrations, it’s the perfect companion for residents and medical students. After your 7-day trial has ended, you will receive a download link for your exclusive e-book.</p>
</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="https://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="https://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul>
	<a class="steady-login-button" data-size="medium" data-language="en" style="display: none;"></a>
</footer>
</body>
</html>
